Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected nigerian adults: Preliminary findings from the START study

HIV/AIDS - Research and Palliative Care

Volumn 4, Issue , 2012, Pages 87-94

  Jeremiah, Zaccheaus A ^a   Obazee, Yetunde ^b   Okogun, Godwin R ^c   Adias, Teddy C ^d   Mgbere, Osaro ^e,f   Essien, Ekere J ^f  

^a NIGER DELTA UNIVERSITY   (Nigeria)

^b General Hospital   (Nigeria)

^c AMBROSE ALLI UNIVERSITY   (Nigeria)

^d Ogbia   (Nigeria)

^e Houston Department of Health and Human Services   (United States)

^f UNIVERSITY OF HOUSTON   (United States)

Author keywords

D dimer; Fibrinolytic markers; PAI 1; START study; t PA

Indexed keywords

ANTIRETROVIRUS AGENT; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NIGERIA; PATIENT ASSESSMENT; PROTEIN DETERMINATION; TREATMENT DURATION;

EID: 84871659598     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S29027     Document Type: Article

References (19)

1. Murphy EL, Collier AC, Kalish LA, et al. Highly active anti-retroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17-26.
2. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000;31(3): 787-797.
3. Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitor rise and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis. 2003;37(7):959-972.
4. Gorog DA. Prognostic value of plasma fibrinolysis activation markers in cardiovascular diseases. J Am Coll Cardiol. 2010;55(24): 2701-2709.
5. Nordenham A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest. 1998;58(6):475-483.
6. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest Suppl. 1999;230:23-31.
7. May M, Lawlor DA, Patel R, Rumley A, Lowe G, Ebrahim S. Association of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study. Eur J Cardiovasc Prev Rehabil. 2007;14(5):638-645.
8. Crum NF, Riffenburgh RH, Wegner S, et al. Comparison of causes of death and mortality rates among HIV-infected persons: analysis of pre-early, and late HAART (highly active antiretroviral therapy) eras. J Aquire Immune Defc Syndr. 2006;41(2):194-200.
9. Valdez H, Connick E, Smith K Y, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 2002;16(14):1859-1866.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
11. Hansson CK, Libby P, Schönbeck U, Ya n ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4):281-291.
12. Nguemaim NF, Mbuagbaw J, Nkoa T, et al. Changes in lipid profiles in two groups of HIV-1 infected patients in Cameroon on two treatment regimens with either Efavirenz or Nevirapine, in association with reverse transcriptase inhibitors. J Med Sci. 2010;10(2):25-33.
13. Nguemain NF, Mbuagbaw J, Nkoa T, et al. Serum lipid profile in highly active antiretroviral therapy-naïve-HIV infected patients in Cameroon: a case-control study. HIV Med. 2010;11(6):353-359.
14. Beerasconi E, Uhr M, Magenta L, Ranno A, Telenti A, Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS. 2001;15(8): 1081-1082.
15. Koppel K, Bratt G, Schulman S, Bylund H, Sandström E. Hypofibrinolytic state in HIV infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Aquir Immune Defc Syndr. 2002; 29(5):441-449.
16. Folsom AR. Fibrinolytic factors and atherothrombotic events: epidemiological evidence. Ann Med. 2000;32 Suppl 1:85-91.
17. George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med. 1999;107(6):624-630.
18. Jacobson MC, Dezube BJ, Aboulafa DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis. 2004;39(8): 1214-1222.
19. Crum-Cianfone N F, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS. 2008;22(10):771-778.